I’m struggling to understand how the entire medical & media infrastructure can be so invested in a novel drug with the potentially catastrophic risk profile of molnupiravir when there’s a standard FDA-approved SSRI that performed just as well in a widely lauded large-scale RCT
Molnupiravir caused such significant harm to fetuses in animal models that Merck has suggested ensuring contraceptive use during *and* after treatment, actively generates mutations that could theoretically lead to new variants & has a mechanism of action that may cause cancer
Fluvoxamine is a pretty standard SSRI with a standard SSRI risk profile that’s been FDA-approved to treat depression, OCD and anxiety disorders for nearly 15 years. Both appear to reduce hospitalizations by roughly 30% in rigorous clinical trials.
Fluvoxamine is also cheaper than molnupiravir by one or two orders of magnitude and has a mountain of real-world safety data. Assuming you trust the data, it’s hard to imagine why anyone giving or receiving COVID treatment would prefer molnupiravir
• • •
Missing some Tweet in this thread? You can try to
force a refresh
